Biologics targeting type 2 inflammation show strong efficacy in eosinophilic COPD, while non-type 2 approaches remain ...

Klaus Rabe, MD, PhD, chest physician and professor of medicine, University of Kiel, discusses improvements in lung function observed in patients enrolled in the BOREAS trial. The results of the BOREAS ...

Bhatt’s study, "Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts,” was recently published in The New England Journal of Medicine. Bhatt and colleagues conducted a multicenter ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. “Type 2 myocardial infarction occurs due to a mismatch ...

GlaxoSmithKline (($GSK)) announced an update on their ongoing clinical study. GlaxoSmithKline (GSK) is launching a new clinical study titled A ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The phase 3 BOREAS trial included adults with ...

When you are living with a chronic lung disease, like chronic obstructive pulmonary disease (COPD), every breath matters and ...